Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 6/20 | 0.32 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | FLT3 | P36888 | 1/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8198191 | 0.82 | PGR (0.38) | KCNH2HRH3BACE1PGRNR3C1 | |
| SCHEMBL7553113 | 0.69 | PGR (0.37) | BACE1PGRNR3C1AR | |
| SCHEMBL12318037 | 0.64 | CCR1 (0.50) | KCNH2HRH3BACE1PGRNR3C1 | |
| SCHEMBL8195208 | 0.64 | BACE1 (0.44) | HRH3BACE1PGRAR | |
| SCHEMBL8192715 | 0.63 | PGR (0.44) | BACE1PGRNR3C1AR | |
| SCHEMBL7574731 | 0.63 | PGR (0.39) | KCNH2HRH3BACE1PGRNR3C1 | |
| SCHEMBL12173645 | 0.62 | BACE1 (0.41) | BACE1PGR | |
| SCHEMBL7566575 | 0.62 | PGR (0.43) | BACE1PGRNR3C1AR | |
| SCHEMBL13466955 | 0.61 | BACE1 (0.62) | KCNH2BACE1PGRNR3C1AR | |
| SCHEMBL12174207 | 0.61 | BACE1 (0.48) | BACE1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183252-B2 | Heterocyclic aspartyl protease inhibitors | SCHERING CORPORATION (US) | 2012-05-22 | — | — | US | disclosed |
| US-20100292203-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292203-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | CHRM1, CHRM2, PRSS1 | KCNH2 3810/4885HRH3 354/4885BACE1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.